Growth Metrics

Biomarin Pharmaceutical (BMRN) Current Deferred Revenue (2016 - 2017)

Biomarin Pharmaceutical's Current Deferred Revenue history spans 5 years, with the latest figure at $17.4 million for Q3 2017.

  • For the quarter ending Q3 2017, Current Deferred Revenue changed N/A year-over-year to $17.4 million, compared with a TTM value of $17.4 million through Sep 2017, changed N/A, and an annual FY2016 reading of $985000.0, changed N/A over the prior year.
  • Current Deferred Revenue for Q3 2017 was $17.4 million at Biomarin Pharmaceutical, up from $985000.0 in the prior quarter.
  • The five-year high for Current Deferred Revenue was $17.4 million in Q3 2017, with the low at $985000.0 in Q4 2016.